St. Louis school grants rights to nasal COVID-19 vaccine

By The Science Advisory Board staff writers

Precision Virologics and Bharat Biotech obtained the rights for a new chimp-adenovirus COVID-19 vaccine from Washington University School of Medicine in St. Louis.

Precision Virologics has optioned the rights to offer the intranasal vaccine in the U.S., Europe, and Japan, and Bharat has obtained a license for all other markets.

In mouse studies, a single nasal dose has shown protection against the virus. Based on these findings, the U.S. National Institutes of Health is advancing studies in nonhuman primates, according to the companies.

Copyright © 2020

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?